Zevaquenabant

Overview

Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD).

Application

Products | Products > Disease Areas > Pain | Products > Disease Areas > Obesity | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Lipid Metabolism | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > Cannabinoid Receptor | Products > Signaling Pathways > NO Synthase

Product Information

• Catalog No.: HY-141411A
• CAS No.: 1998760-00-1
• Molecular Formula: C25H21ClF3N5O2S
• Molecular Weight: 547.98
• Purity: 99.64%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (9.12 mM); Clear solution
• Availability: In-stock

Source

Original product source